Literature DB >> 11468205

Exercise pathophysiology in patients with primary pulmonary hypertension.

X G Sun1, J E Hansen, R J Oudiz, K Wasserman.   

Abstract

BACKGROUND: Patients with primary pulmonary hypertension (PPH) have a pulmonary vasculopathy that leads to exercise intolerance due to dyspnea and fatigue. To better understand the basis of the exercise limitation in patients with PPH, cardiopulmonary exercise testing (CPET) with gas exchange measurements, New York Heart Association (NYHA) symptom class, and resting pulmonary hemodynamics were studied. METHODS AND
RESULTS: We retrospectively evaluated 53 PPH patients who had right heart catheterization and cycle ergometer CPET studies to maximum tolerance as part of their clinical workups. No adverse events occurred during CPET. Reductions in peak O(2) uptake (VO(2)), anaerobic threshold, peak O(2) pulse, rate of increase in VO(2), and ventilatory efficiency were consistently found. NYHA class correlated well with the above parameters of aerobic function and ventilatory efficiency but less well with resting pulmonary hemodynamics.
CONCLUSIONS: Patients with PPH can safely undergo noninvasive cycle ergometer CPET to their maximal tolerance. The CPET abnormalities were consistent and characteristic and correlated well with NYHA class.

Entities:  

Mesh:

Year:  2001        PMID: 11468205     DOI: 10.1161/hc2901.093198

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  116 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 2.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 3.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

4.  Prognostic value of capnography during rest and exercise in patients with heart failure.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Paul Chase; Daniel Bensimhon; Lawrence P Cahalin; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman
Journal:  Congest Heart Fail       Date:  2012-04-26

5.  Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension.

Authors:  G Valli; C D Vizza; P Onorati; R Badagliacca; R Ciuffa; R Poscia; F Brandimarte; F Fedele; P Serra; P Palange
Journal:  Eur J Appl Physiol       Date:  2007-11-03       Impact factor: 3.078

6.  Right-sided heart failure: diagnosis and treatment strategies.

Authors:  Jennifer Cowger Matthews; Todd F Dardas; Michael P Dorsch; Keith D Aaronson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

7.  Detection of exercise-induced pulmonary arterial hypertension by cardiopulmonary exercise testing.

Authors:  Martin Schwaiblmair; Christian Faul; Wolfgang von Scheidt; Thomas M Berghaus
Journal:  Clin Cardiol       Date:  2012-05-15       Impact factor: 2.882

Review 8.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

9.  Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Hui-Juan Ni; Tian-Xiang Chen; Bigyan Pudasaini; Rong Jiang; Hui Liu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Jin-Ming Liu
Journal:  Hypertens Res       Date:  2017-06-01       Impact factor: 3.872

10.  Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Emmy Manders; Peter I Bonta; Jaap J Kloek; Petr Symersky; Harm-Jan Bogaard; Pleuni E Hooijman; Jeff R Jasper; Fady I Malik; Ger J M Stienen; Anton Vonk-Noordegraaf; Frances S de Man; Coen A C Ottenheijm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-05-17       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.